Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.
Roma PahwaJanhavi DubhashiAnand SinghParthav JailwalaAlexei LobanovCraig J ThomasMichele CeribelliKelli WilsonChristopher J RickettsCathy D VockeCatherine WellsDonald P BottaroW Marston LinehanLen NeckersRamaprasad SrinivasanPublished in: Journal of experimental & clinical cancer research : CR (2022)
These results demonstrate that HSP90 inhibition is associated with potent activity in PRCC, and implicate the PI3K/AKT and MEK/ERK1/2 pathways as important mediators of tumorigenesis. These data also provide the impetus for further clinical evaluation of HSP90, AKT, MEK or E2F pathway inhibitors in PRCC.